Real-World Effectiveness and Prognostic Factors of Long-Term Lenvatinib Use As First-Line Treatment in Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study in Taiwan

Author(s)

Lin YJ1, Chang KC2, Chen HY3
1Linkou Chang Gung Memorial Hospital, Taoyuan, TAO, Taiwan, 2Linkou Chang Gung Memorial Hospital, Taoyuan City, Taiwan, 3Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan, Taiwan

OBJECTIVES: Lenvatinib is approval as first-line treatment of patients with advanced hepatocellular carcinoma (HCC). However, the real-world effectiveness of long-term uses was limited. We aimed to analyze prognostic factors and effectiveness on long-term uses of lenvatinib as first-line in Taiwan.

METHODS: This was a retrospective cohort study by using electronic medication record database in Taiwan. We included the patients with single use of lenvatinib as first-line more than six month from January 2020 to December 2021. The outcomes were overall survival (OS) and the progression-free survival (PFS). We followed each patient from the start using lenvatinib to progression date, death or December 2023. We analyzed baseline and tumor characteristics as prognostic factors, including patients including age, gender, tumor number, size of tumor, portal vein invasion, hepatic vein invasion and presence ascites. Univariable and multivariable Cox regression model was applied for estimating potentially prognostic factors.

RESULTS: We included a total of 117 lenvatinib users with a median age of 64.2 years (SD 12.1) and a median duration of lenvatinib use of 424.0 days (SD 330.4). Of the 117 users, 81.2% were male, and 12.82% had ascites. Additionally, 56.4% of the patients had multiple tumors, 20.51% had a single tumor, 6.8% had hepatic vein invasion, and 47.9% had portal vein invasion. The overall survival (OS) and progression-free survival (PFS) were 24.5 months (21.1 to 32.1) and 13.4 months (11.1 to 17.3), respectively. Based on Cox regression model, hepatic vein invasion was associated with poor OS (HR: 2.4; 95% CI: 1.02-5.58).

CONCLUSIONS: The study demonstrated that long-term use of lenvatinib as a first-line treatment for advanced hepatocellular carcinoma in Taiwan. Hepatic vein invasion was identified as a significant prognostic factor associated with poorer overall survival.

Conference/Value in Health Info

2024-11, ISPOR Europe 2024, Barcelona, Spain

Value in Health, Volume 27, Issue 12, S2 (December 2024)

Code

RWD75

Topic

Clinical Outcomes

Topic Subcategory

Comparative Effectiveness or Efficacy

Disease

Oncology, Personalized & Precision Medicine

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×